Does Regence Cover Eliquis? A Woman's Guide to Insurance, Costs, and What to Ask

What Is Eliquis and Why Do Women Get Prescribed It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that works by blocking Factor Xa in the clotting cascade. Your cardiologist, OB-GYN, or internist may prescribe it to treat or prevent deep vein thrombosis (DVT), pulmonary embolism (PE), or to reduce stroke risk in nonvalvular atrial fibrillation (AFib).

Women are not a minor subgroup in this story. Venous thromboembolism (VTE) affects roughly 900,000 Americans each year, and women carry sex-specific risk factors that men simply do not: oral contraceptive pills, hormonal IUDs in certain contexts, pregnancy itself, postpartum recovery, and menopausal hormone therapy (MHT). The risk of VTE is 3 to 8 times higher during pregnancy and the postpartum period than in age-matched non-pregnant women, according to ACOG Practice Bulletin No. 196.

AFib also affects women differently. Women with AFib have a higher absolute stroke risk than men with the same CHA2DS2-VASc score, which is one reason sex is now factored into European and some U.S. Stroke-risk calculators. If your provider prescribes Eliquis, the question of whether Regence will pay for it is not an administrative footnote. It is a safety question.

Who Gets Eliquis Most Often

Women most commonly receive Eliquis prescriptions for:

• Acute DVT or PE treatment (typically 10 mg twice daily for 7 days, then 5 mg twice daily)
• Extended DVT/PE prevention after the acute phase (2.5 mg twice daily)
• Nonvalvular AFib stroke prevention (5 mg twice daily, or 2.5 mg twice daily if two of three dose-reduction criteria are met)

Each of these FDA-approved indications affects how Regence codes and covers the prescription, so the diagnosis on your prescription matters as much as the drug itself.

How Regence Formularies Work and Where Eliquis Usually Lands

Regence BlueCross BlueShield operates across Oregon, Washington, Idaho, and Utah, offering individual, employer-group, and Medicare Advantage plans. Each plan has its own formulary, updated annually, but a consistent pattern holds across most Regence commercial plans.

The Tier System Explained

| Tier | Category | Typical Member Copay | |------|----------|----------------------| | Tier 1 | Preferred generics | $5, $15 | | Tier 2 | Non-preferred generics / preferred brands | $30, $60 | | Tier 3 | Non-preferred brands | $60, $120 | | Tier 4 | Specialty drugs | 20 to 30% coinsurance |

Eliquis consistently sits at Tier 3 on most Regence commercial formularies because no FDA-approved generic exists yet, meaning Bristol-Myers Squibb and Pfizer retain branded pricing power. The FDA has not approved a generic apixaban as of the date of this article, though patent litigation is ongoing.

For Medicare Advantage and Part D plans administered by Regence, Eliquis is covered under Part D but may sit in a higher cost-sharing tier depending on the specific plan year and region.

Prior Authorization: The Gatekeeper Step

Most Regence plans require prior authorization (PA) for Eliquis. That means your prescriber must submit clinical documentation showing that Eliquis is medically necessary, typically by confirming an approved diagnosis (DVT, PE, or nonvalvular AFib) and, in some cases, demonstrating a reason a cheaper anticoagulant was not used first. Common PA requirements include:

• Confirmed diagnosis via ICD-10 code (e.g., I48.x for AFib, I82.x for DVT)
• Documentation of allergy or intolerance to warfarin, or clinical reason for preferring a DOAC
• INR monitoring challenges or lability if warfarin was previously trialed

If PA is denied, your provider can file an appeal or a peer-to-peer review request. Appeals for prior authorization denials overturn the original decision in 40 to 75 percent of cases depending on plan type, so a denial is not the final answer.

Step Therapy: Do You Have to Try Warfarin First?

Some Regence plans impose step therapy, requiring documented use of warfarin before approving Eliquis. This is clinically contested territory. The American Heart Association and American College of Cardiology do not recommend warfarin as a preferred first-line agent over DOACs for nonvalvular AFib in most patients. If your plan demands step therapy but your provider has a clinical reason to start Eliquis directly (e.g., labile INR risk, patient preference with documented counseling, or history of falls that makes INR monitoring difficult), that rationale should be included in the PA letter.

How Much Will You Actually Pay? Real Cost Scenarios

Your out-of-pocket cost depends on which Regence plan you have and whether you are in your deductible phase, copay phase, or out-of-pocket maximum phase for the year.

Scenario 1: Employer-Sponsored Plan, Deductible Not Met

At a cash price of roughly $600 for a 30-day supply, you would pay the full amount until your deductible is satisfied. If your deductible is $1,500, you hit it in about 2.5 months of Eliquis alone.

Scenario 2: Employer-Sponsored Plan, Deductible Met, Tier 3 Copay

A Tier 3 copay of $80 to $120 per 30-day fill is typical once your deductible is satisfied on a standard Regence commercial plan.

Scenario 3: Regence Medicare Advantage Part D

Costs vary by plan year and region. In 2025, the Inflation Reduction Act capped out-of-pocket drug spending for Medicare Part D beneficiaries at $2,000 per year, which meaningfully protects older women on fixed incomes who need long-term anticoagulation.

The BMS/Pfizer Copay Card

Bristol-Myers Squibb and Pfizer offer a copay assistance card for commercially insured patients. Eligible patients pay as little as $10 per 30-day supply, with a cap of $6,400 per year in savings. Key restrictions:

• Not available for Medicare, Medicaid, CHIP, TRICARE, or any other federal or state program
• Must be a U.S. Resident with commercial insurance (Regence commercial plans qualify)
• Enrollment is free and can be done online or by phone

If you are on a Regence commercial plan and your copay is $100/month, the copay card can reduce that to $10. This is the single highest-use action for most working-age women on Regence commercial coverage.

Women-Specific Pharmacology of Apixaban

This section matters because most published DOAC trial data was collected in predominantly male cohorts, and the sex-specific data takes work to find. Women were underrepresented in early DOAC trials, comprising only 35 to 40 percent of the ARISTOTLE trial population, the landmark apixaban AFib study published in the New England Journal of Medicine in 2011.

What we do know from available subgroup analyses:

• Body weight matters more for women. Apixaban dose reduction criteria (use 2.5 mg twice daily if two of the following are met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) disproportionately affect smaller-framed women. The FDA label specifies these criteria and your pharmacist should flag this automatically, but it is worth confirming.

• Bleeding risk differs by sex. In the ARISTOTLE trial, women had a lower rate of intracranial hemorrhage than men, a pattern consistent across most DOAC trials. However, gastrointestinal bleeding rates were similar.

• Renal function changes across the menstrual cycle. Creatinine clearance fluctuates slightly across cycle phases, which is unlikely to affect dosing in women with normal kidneys but may matter at the margins for women near the dose-reduction threshold.

A Life-Stage Framework for Eliquis Prescribing in Women

Reproductive years (ages 18 to 45): The most common trigger for Eliquis in this group is acute VTE associated with combined oral contraceptive pills, which increase clot risk 3 to 6-fold compared to non-users. After a first pill-associated VTE, most guidelines recommend stopping the combined OCP and switching to a progestin-only or non-hormonal method. Eliquis is prescribed for 3 to 6 months of acute treatment in uncomplicated DVT/PE, and possibly longer if clotting risk remains elevated.

Trying to conceive (TTC): If you are planning pregnancy and need anticoagulation, a transition to low-molecular-weight heparin (LMWH) such as enoxaparin before conception attempts is standard of care. Eliquis must not be used during pregnancy. Discuss timing with your hematologist and OB-GYN before stopping contraception.

Perimenopause (ages 40 to 55, approximately): Estrogen fluctuations in perimenopause do not directly interact with apixaban metabolism (it is primarily metabolized by CYP3A4 and P-gp), but AFib incidence rises with age and many perimenopausal women are also evaluating MHT. Systemic estrogen-containing MHT carries a modestly elevated VTE risk, particularly oral formulations. Transdermal estradiol carries significantly lower VTE risk than oral estrogen, a distinction that matters if you and your provider are weighing MHT alongside anticoagulation.

Post-menopause: AFib prevalence rises steadily after menopause. If you are on Regence Medicare Advantage and have been prescribed Eliquis for stroke prevention in AFib, the $2,000 annual Part D cap introduced under the Inflation Reduction Act gives meaningful protection. Ask your pharmacist about Extra Help (Low Income Subsidy) if your income qualifies.

Pregnancy, Lactation, and Contraception: Non-Negotiable Information

Eliquis is contraindicated in pregnancy. This is not a cautionary statement. It is a hard stop.

Pregnancy

Apixaban crosses the placenta. Animal reproduction studies showed fetal harm at doses that produce plasma exposures comparable to human therapeutic doses. The FDA product label carries a warning that apixaban may cause fetal harm and should be avoided during pregnancy. There are no adequate and well-controlled studies in pregnant women, and existing case reports are insufficient to establish safety.

If you become pregnant while taking Eliquis, contact your prescriber immediately. You will likely be transitioned to LMWH, which does not cross the placenta and has a well-established safety record in pregnancy. ACOG and the American Society of Hematology both recommend LMWH as the anticoagulant of choice throughout pregnancy for women with VTE or mechanical heart valves.

Contraception Requirements

Because an unplanned pregnancy on Eliquis poses serious fetal risk, all women of reproductive age taking this drug should use reliable contraception. The most effective options are:

• Copper IUD (zero hormonal effect, no clot risk)
• Levonorgestrel IUD (minimal systemic absorption, generally considered low clot risk)
• Progestin-only pill (no estrogen, lower VTE risk than combined OCP)
• Barrier methods combined with a highly effective method above

Combined estrogen-progestin contraceptives are generally avoided in women already being anticoagulated for a prior VTE, as they compound the underlying clotting risk.

Lactation

Apixaban is not recommended during breastfeeding. Animal data shows it is present in breast milk, and the effects on a nursing infant are unknown. The FDA label advises against breastfeeding while taking Eliquis. If you have a postpartum VTE requiring anticoagulation and wish to breastfeed, discuss LMWH or warfarin with your provider. Warfarin is considered compatible with breastfeeding by most guidelines because it does not appear in breast milk in clinically significant amounts.

How to Get Regence to Cover Eliquis: A Step-by-Step Approach

Navigating a prior authorization or coverage dispute is frustrating, but a systematic approach gets results.

Step 1: Confirm Your Plan's Specific Formulary

Regence formularies change annually. Go to the Regence member portal, log in, and search "apixaban" or "Eliquis" in the drug search tool. Note the tier and any PA or step-therapy requirement listed for your plan year.

Step 2: Ask Your Prescriber to Submit the PA

Your prescriber's office should handle PA submission. Give them your Regence member ID and plan name. Make sure the PA includes:

• Your confirmed diagnosis with ICD-10 code
• Clinical rationale for Eliquis specifically
• Any warfarin intolerance or INR instability history
• For women: any pregnancy-related or hormonal context if relevant

Step 3: If PA Is Denied, Request Peer-to-Peer Review

Many denials are overturned when the prescribing physician speaks directly to the Regence medical director. Your provider's office can request this call within the PA appeal window, typically 14 to 60 days depending on plan type and state.

Step 4: File a Formal Appeal

If peer-to-peer fails, a written appeal with supporting literature (including AHA/ACC guideline statements) can be submitted. Oregon, Washington, Idaho, and Utah each have state insurance commissioner offices that handle external appeals if the internal appeal fails.

Step 5: Apply for the BMS Copay Card Immediately

Do not wait for the PA fight to resolve before applying for the copay card if you have commercial insurance. You can apply at the BMS patient assistance portal and start saving from your first fill. This reduces your exposure while the insurance issue is sorted.

Step 6: Ask About 90-Day Supplies

Many Regence plans offer a lower effective per-day copay for 90-day mail-order supplies through their preferred pharmacy benefit manager. This does not lower the tier but may reduce total annual cost.

Who Eliquis Is and Is Not Right For, by Life Stage

Understanding whether Eliquis is the right anticoagulant for your situation is as important as knowing how to pay for it.

Women Who Are Typically Good Candidates

• Reproductive-age women with an acute DVT or PE requiring 3 to 6 months of treatment, using reliable non-estrogen contraception
• Perimenopausal or postmenopausal women with nonvalvular AFib and a CHA2DS2-VASc score of 2 or higher (with female sex as one point)
• Women who had INR instability on warfarin or who cannot manage regular INR monitoring
• Women with a first DVT provoked by OCP use who are switching to progestin-only or non-hormonal contraception

Women Who Are Not Candidates

• Pregnant women. Transition to LMWH.
• Breastfeeding women who prefer to avoid any drug exposure to their infant. Discuss LMWH or warfarin with your provider.
• Women with severe renal impairment (CrCl <15 mL/min), for whom data is insufficient
• Women with mechanical heart valves. DOACs including Eliquis are contraindicated in this setting; warfarin remains standard.
• Women with active pathological bleeding or a high bleeding-risk condition where anticoagulation risk outweighs benefit

The Evidence Gap: What We Still Do Not Know About Eliquis in Women

Honesty about the evidence matters here. The ARISTOTLE trial enrolled approximately 18,000 patients but only 35 percent were women. Sex-specific subgroup analyses suggest similar relative risk reduction in women compared to men, but the absolute number of women in each subgroup is small enough that sex-specific confidence intervals are wide.

For women with PCOS, a condition associated with elevated VTE risk due to insulin resistance and, in some cases, OCP use for symptom management, there are no dedicated DOAC trials. PCOS affects roughly 6 to 12 percent of reproductive-age women and frequently intersects with the conditions for which Eliquis is prescribed, yet this population is effectively absent from the published trial literature.

For women with antiphospholipid syndrome (APS), a condition far more prevalent in women than men, the TRAPS trial found that rivaroxaban was inferior to warfarin in triple-positive APS, and by extension most guidelines recommend against DOACs in high-risk APS. Apixaban-specific APS data remains limited, and warfarin should be considered the standard until stronger data emerges.

These gaps are not reasons to avoid Eliquis when it is indicated. They are reasons to have a specific, informed conversation with your prescriber about whether the available data applies to your individual situation.

Frequently Asked Questions